COOPER COMPANIES, INC.

Listed Company

COOCIK 0000711404NasdaqLarge AcceleratedOphthalmic GoodsDelawareFY ends Oct 31

Period

FY 2025

Revenue

$4.09B

Net Income

$374.90M

Total Assets

$12.39B

Equity

$8.24B

Shares Out

195.11M

Op. Cash Flow

$796.10M

Business

COOPER COMPANIES, INC. is a global medical device company focused on vision, fertility and women’s health. It develops, manufactures and markets contact lenses, myopia management lenses, medical devices, fertility products and services, cryostorage, donor gametes, genomic services and a hormone-free IUD. The company operates through two business segments, CooperVision (soft contact lens design, production and myopia management) and CooperSurgical (fertility and women's health devices, services and cryostorage). Its products are sold worldwide through field sales, distributors, eye care practitioners, hospitals, ambulatory surgery centers, fertility clinics and direct-to-consumer channels.

Summary from filing dated 2025-12-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-10-31	FY 2024 2024-10-31	FY 2023 2023-10-31	FY 2022 2022-10-31	FY 2021 2021-10-31
Net sales	4,092	3,895	3,593	3,308	2,923
Cost of sales	1,410	1,300	1,235	1,169	967
Gross profit	2,682	2,596	2,358	2,140	1,956
Selling, general and administrative expense	1,628	1,534	1,501	1,342	1,211
Research and development expense	172	155	137	110	93
Amortization of intangibles	199	201	186	180	146
Operating income	683	706	533	508	506
Interest expense	100	114	105	57	—
Other expense	16	9	15	−25	−9
Income before income taxes	567	582	413	475	492
Provision for income taxes (Note 6)	192	190	119	90	−2,453
Net income	375	392	294	386	2,945
Basic (in dollars per share)	1.88	1.97	1.49	1.95	59.8
Diluted (in dollars per share)	1.87	1.96	1.48	1.94	59.16
Basic (in shares)	199	199	198	197	49
Diluted (in shares)	200	200	199	199	50

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-10-31	FY 2024 2024-10-31	FY 2023 2023-10-31	FY 2022 2022-10-31	FY 2021 2021-10-31
Cash and cash equivalents	111	108	121	138	96
Trade accounts receivable, net of allowance for credit losses of $51.9 at October 31, 2025 and $43.5 at October 31, 2024	829	717	610	558	515
Inventories (Note 1)	846	803	736	629	586
Prepaid expense and other current assets	321	324	239	209	179
Total current assets	2,106	1,952	1,705	1,534	1,465
Property, plant and equipment, net	2,082	1,863	1,633	1,433	1,348
Goodwill (Note 4)	3,853	3,838	3,625	3,610	2,574
Other intangibles, net (Note 4)	1,586	1,791	1,710	1,885	1,272
Deferred tax assets	2,078	2,210	2,350	2,443	2,547
Other assets	689	661	637	588	401
Total assets	12,395	12,315	11,659	11,492	9,606
Short-term debt (Note 5)	48	33	45	413	83
Accounts payable	300	261	262	249	161
Employee compensation and benefits	211	175	175	152	149
Deferred revenue	128	130	124	94	19
Other current liabilities	426	424	363	373	318
Total current liabilities	1,113	1,023	969	1,280	732
Long-term debt (Note 5)	2,458	2,550	2,524	2,351	1,398
Deferred tax liabilities	93	96	102	150	24
Long-term tax payable	8	58	90	113	140
Deferred revenue	202	193	184	198	100,000
Other liabilities	283	312	239	225	—
Total liabilities	4,156	4,232	4,108	4,318	2,664
Contingencies (Note 11)	—	—	—	—	—
Preferred stock, $0.10 par value, 1.0 shares authorized, zero shares issued or outstanding	0	0	0	0	0
Common stock, $0.10 par value, 480.0 shares authorized, 217.6 issued and 195.9 outstanding at October 31, 2025 and 217.2 issued and 199.6 outstanding at October 31, 2024	22	22	22	5	5
Additional paid-in capital	1,976	1,921	1,817	1,766	1,715
Accumulated other comprehensive loss	−407	−422	−454	−467	−341
Retained earnings	7,643	7,268	6,876	6,585	6,202
Treasury stock at cost: 21.7 shares at October 31, 2025 and 17.6 shares at October 31, 2024	−995	−706	−710	−715	−640
Total Cooper stockholders' equity	8,239	8,083	7,551	7,175	6,942
Noncontrolling interests	200,000	200,000	200,000	200,000	200,000
Stockholders equity (Note 8)	8,239	8,084	7,551	7,175	6,942
Total liabilities and stockholders equity	12,395	12,315	11,659	11,492	9,606

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-10-31	FY 2024 2024-10-31	FY 2023 2023-10-31	FY 2022 2022-10-31	FY 2021 2021-10-31
Depreciation and amortization	377	375	368	346	309
Share-based compensation expense	71	75	62	54	44
Non-cash operating lease expense	46	39	40	32	32
Other including asset impairment charges	77	43	49	5	−5
Change in fair value of contingent consideration	0	0	−32	−10	66
Deferred income taxes	135	119	45	54	−2,502
Accounts receivable	−120	−117	−60	−34	−76
Inventories	−46	−59	−105	−40	−9
Other assets	−75	−133	−89	−17	−69
Operating lease right-of-use assets and liabilities, net	−47	−42	−34	−51	−28
Accounts payable	8	9	6	50	−16
Accrued liabilities	28	4	72	32	59
Accrued income taxes	−52	−15	−500,000	−27	10
Other long-term liabilities	19	20	−6	−34	−22
Net cash provided by operating activities	796	709	608	692	739
Purchases of property, plant and equipment	−362	−421	−393	−242	−214
Acquisitions of businesses and assets, net of cash acquired, and other	−11	−343	−57	−1,641	−236
Net cash used in investing activities	−373	−765	−449	−1,831	−450
Proceeds from long-term debt, net of issuance costs	3,111	3,524	2,124	1,511	1,427
Repayments of long-term debt	−3,205	−3,507	−1,954	−562	−1,416
Net proceeds from (repayments of) short-term debt, other	14	−12	−351	329	−321
Repurchase of common stock	−290	0	0	−79	−25
Proceeds related to share-based compensation awards	5	56	15	9	34
Payments related to share-based compensation awards	−25	−30	−13	−17	−13
Dividends on common stock	0	0	−3	−3	−3
Issuance of common stock for employee stock purchase plan	11	8	8	7	6
Acquisition installment payment	−47	0	0	—	—
Net cash provided (used in) by financing activities	−426	39	−174	1,194	−311
Effect of exchange rate changes on cash, cash equivalents and restricted cash	6	3	−2	−13	3
Net increase (decrease) in cash, cash equivalents and restricted cash	3	−13	−18	42	−20
Interest	115	135	118	49	28
Income taxes	100	78	68	67	63
Operating lease liabilities	50	48	48	45	37
Operating lease ROU assets obtained in exchange for lease obligations	53	55	43	30	27

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro